Unraveling the potential of ALK-targeted therapies in non-small cell lung cancer: comprehensive insights and future directions
H Parvaresh, G Roozitalab, F Golandam, P Behzadi… - Biomedicines, 2024 - mdpi.com
Background and Objective: This review comprehensively explores the intricate landscape of
anaplastic lymphoma kinase (ALK), focusing specifically on its pivotal role in non-small cell …
anaplastic lymphoma kinase (ALK), focusing specifically on its pivotal role in non-small cell …
Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update
J Moes-Sosnowska, A Szpechcinski… - Tumor …, 2023 - content.iospress.com
The development of targeted therapies for non-small cell lung cancer (NSCLC), such as the
epidermal growth factor receptor (EGFR), anaplastic lymphoma receptor tyrosine kinase …
epidermal growth factor receptor (EGFR), anaplastic lymphoma receptor tyrosine kinase …
[HTML][HTML] Integrated network pharmacology and in-silico approaches to decipher the pharmacological mechanism of Selaginella tamariscina in the treatment of non …
Background and purpose Non-small cell lung cancer (NSCLC) is a major pathological type
of lung cancer and accounts for more than 80% of all cases. In healthcare management, it is …
of lung cancer and accounts for more than 80% of all cases. In healthcare management, it is …
Postoperative pathological complete response in a patient with PD‑L1‑negative stage IIIB lung squamous cell carcinoma following neoadjuvant tislelizumab treatment …
G Cui, D Qu, Y Bai, X Sun, Y Li… - Oncology …, 2023 - spandidos-publications.com
The utilization of immune checkpoint inhibitors in oncological treatment has increased in
recent years. The therapeutic strategy of targeting the programmed death‑1 (PD …
recent years. The therapeutic strategy of targeting the programmed death‑1 (PD …
FAT4 activation inhibits epithelial-mesenchymal transition (EMT) by promoting autophagy in H2228/Cer cells
Y Yang, Y Li, Q Yang, Z Liu, X Chang, H Yang, J Liu… - Medical Oncology, 2022 - Springer
As a tumor suppressor in lung cancer, FAT atypical cadherin 4 (FAT4) has a critical role in
epithelial-mesenchymal transition (EMT). However, the role of FAT4 in ceritinib-resistant …
epithelial-mesenchymal transition (EMT). However, the role of FAT4 in ceritinib-resistant …
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC)
L Fabbri, A Di Federico, M Astore, V Marchiori… - Diagnostics, 2023 - mdpi.com
Following the results of the CROWN phase III trial, the third-generation macrocyclic ALK
inhibitor lorlatinib has been introduced as a salvage option after the failure of a first-line TKI …
inhibitor lorlatinib has been introduced as a salvage option after the failure of a first-line TKI …
Prediction of trough concentration and ALK occupancy in plasma and cerebrospinal fluid using physiologically based pharmacokinetic modeling of crizotinib, alectinib …
B Li, S Liu, H Feng, C Du, L Wei, J Zhang… - Frontiers in …, 2023 - frontiersin.org
Backgrounds: Brain metastases occur in approximately 30% of patients with non-small-cell
lung cancer (NSCLC). Therefore, the free drug concentration in cerebrospinal fluid (CSF) is …
lung cancer (NSCLC). Therefore, the free drug concentration in cerebrospinal fluid (CSF) is …
Mitoxantrone and abacavir: An ALK protein-targeted in silico proposal for the treatment of non-small cell lung cancer
JE Faya Castillo, RJ Zapata Dongo, PA Wong Chero… - Plos one, 2024 - journals.plos.org
Non-small cell lung cancer (NSCLC) is a type of lung cancer associated with translocation of
the EML4 and ALK genes on the short arm of chromosome 2. This leads to the development …
the EML4 and ALK genes on the short arm of chromosome 2. This leads to the development …
Three Innovative Green and High-Throughput Microwell Spectrophotometric Methods for the Quantitation of Ceritinib, a Potent Drug for the Treatment of ALK-Positive …
RM Abuhejail, NZ Alzoman, IA Darwish - Molecules, 2023 - mdpi.com
Ceritinib (CER) is a potent drug that has been recently approved by the Food and Drug
Administration for the treatment of patients with non-small cell lung cancer harboring the …
Administration for the treatment of patients with non-small cell lung cancer harboring the …
Theranostic applications of peptide-based nanoformulations for growth factor defective cancers
Growth factors play a pivotal role in orchestrating cellular growth and division by binding to
specific cell surface receptors. Dysregulation of growth factor production or activity can …
specific cell surface receptors. Dysregulation of growth factor production or activity can …